Economic effect of the application of three-component schemes with iksasomib or carfilsomib for therapy of multiple myeloma in adult patients

2018 ◽  
Vol 6 (4) ◽  
pp. 10-18
Author(s):  
D.L. Klabukova ◽  
V.S. Krysanov ◽  
K.I. Polyakova ◽  
T.N. Ermolaeva ◽  
M.V. Davydovskaya ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Economic Effect ◽  
Adult Patients

High Number of Successful Mobilizations Associated with the Use of Plerixafor and Colony Stimulating Factors In Patients with Multiple Myeloma (MM) and Lymphoma Treated at Memorial Sloan-Kettering Cancer Center

Blood ◽  
2010 ◽  
Vol 116 (21) ◽  
pp. 2263-2263
Author(s):  
Nelly G. Adel ◽  
Mathew Sherry ◽  
Stephen J. Harnicar ◽  
Emily Mccullagh ◽  
Heather Landau ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Stem Cell ◽  
Adult Patients ◽  
Stem Cell Mobilization ◽  
Cancer Center ◽  
Published Data ◽  
First Line ◽  
Colony Stimulating Factors ◽  
Cd34 Cells ◽  
Cell Mobilization

Abstract Abstract 2263 Background: Autologous stem cell transplantation (ASCT) remains the only curative option for many lymphoma patients and it is an integral component of treatment for patients with multiple myeloma (MM). Stem cell mobilization has most commonly been performed using either chemotherapy and colony-stimulating factors or colony stimulating factors alone. This approach was challenged by the inability to collect enough CD 34 cell count to perform an ASCT. Plerixafor (Mozobil ®) previously known as AMD3100, a selective antagonist of CXCR4, has recently been approved for ASCT mobilization in combination with granulocyte- colony stimulating factor (G-CSF) for both multiple myeloma and lymphoma patients and is effective for patients who failed to mobilize enough CD34 cells with other modalities. Patients and Methods: This retrospective study examines all adult patients with MM and lymphoma who received plerixafor as a mobilization agent for ASCT at Memorial Sloan- Kettering Cancer Center between January 1st, 2009 and August 1st, 2010. Patient's information was obtained from the pharmacy data base and electronic medical records. Data included demographics, diagnosis, first line mobilization regimen, second and third line regimens, doses of plerixafor received, number of pheresis sessions and CD34 cells per kg collected per each session. The primary objective was to determine how many patients failed stem cell collection following mobilization at our center. Results: Fifty-six adult patients with lymphoma (N=23) and MM (N=33) were identified. Patients were excluded if they were treated for a pediatric malignancy or an alternate diagnosis. The average number of pheresis and CD34 cells/kg collected in each group are shown Table 1. Forty-three percent (10/23) patients with lymphoma received plerixafor and G-CSF as the first line option for mobilization and 57% (13/23) received plerixafor and G-CSF after failing other regimens. A total of 5 (22%) patients with lymphoma failed collection following mobilization with plerixafor, 1 as a primary mobilization failure and 4 having failed other mobilization strategies. Thirty-nine percent (13/33) of patients with MM received plerixafor and G-CSF as the first line option for mobilization and 61% (20/33)after failing other regimens, including cyclophosphamide (N=15) and G-CSF alone (N=5). Among the patients mobilized with plerixafor, 6% (2/33) failed collection, 1 who received plerixafor and G-CSF for primary mobilization and only 1 after failing other regimens. Conclusion: In lymphoma and MM patients plerixafor in combination with G-CSF is effective for stem cell mobilization and in this study we report higher success rates than in previously published data. The few number of failures with plerixafor plus G-CSF given as a primary mobilization regimen, supports its use in this setting and is attractive considering that it can reduce patient's exposure to chemotherapy. Disclosures: Matasar: Genzyme Pharmaceuticals: Membership on an entity's Board of Directors or advisory committees.

scholarly journals EMA Review of Daratumumab for the Treatment of Adult Patients with Multiple Myeloma

2018 ◽  
Vol 23 (5) ◽  
pp. 594-602 ◽  
Author(s):  
Kyriaki Tzogani ◽  
Elisabeth Penninga ◽  
Marie Louise Schougaard Christiansen ◽  
Doris Hovgaard ◽  
Sinan B. Sarac ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Adult Patients

scholarly journals 4CPS-103 Evaluation of health outcomes of daratumumab in monotherapy in adult patients with relapsed refractory multiple myeloma

2019 ◽  
Author(s):  
C Alarcon-Payer ◽  
JE Martínez-de la Plata ◽  
S Cano Domínguez ◽  
ME Clavero Sánchez ◽  
R Ríos Tamayo ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Health Outcomes ◽  
Adult Patients ◽  
Refractory Multiple Myeloma

scholarly journals The European Medicines Agency Review of Carfilzomib for the Treatment of Adult Patients with Multiple Myeloma Who Have Received at Least One Prior Therapy

2017 ◽  
Vol 22 (11) ◽  
pp. 1339-1346 ◽  
Author(s):  
Kyriaki Tzogani ◽  
Jorge Camarero Jiménez ◽  
Isabel Garcia ◽  
Arantxa Sancho‐López ◽  
Marc Martin ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Adult Patients ◽  
European Medicines Agency ◽  
Prior Therapy

scholarly journals European Medicines Agency review of ixazomib (Ninlaro) for the treatment of adult patients with multiple myeloma who have received at least one prior therapy

ESMO Open ◽  
2019 ◽  
Vol 4 (5) ◽  
pp. e000570 ◽  
Author(s):  
Kyriaki Tzogani ◽  
Beatriz Florez ◽  
Greg Markey ◽  
Mariapaola Caleno ◽  
Odoardo Maria Olimpieri ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Adult Patients ◽  
Phase Iii ◽  
European Medicines Agency ◽  
P Value ◽  
The European Union ◽  
Double Blind ◽  
Scientific Review ◽  
Triple Combination Therapy ◽  
Prior Therapy

On 21 November 2016, the European Commission issued a marketing authorisation valid throughout the European Union for ixazomib in combination with lenalidomide and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy. Ixazomib was evaluated in one, randomised, double-blind, phase III study comparing ixazomib plus lenalidomide and dexamethasone (n=360; ixazomib arm) versus placebo plus lenalidomide and dexamethasone (n=362; placebo arm) in adult patients with relapsed and/or refractory multiple myeloma who had received at least one prior therapy. The median progression-free survival (PFS) in the intent-to-treat population was 20.6 months in patients treated with ixazomib compared with 14.7 months for patients in the placebo arm (stratified HR=0.742, 95% CI 0.587 to 0.939, stratified p-value=0.012). The most frequently reported adverse reactions (≥20%) within the ixazomib and placebo arms were diarrhoea (42% vs 36%), constipation (34% vs 25%), thrombocytopaenia (28% vs 14%), peripheral neuropathy (28% vs 21%), nausea (26% vs 21%), peripheral oedema (25% vs 18%), vomiting (22% vs 11%) and back pain (21% vs 16%). The scientific review concluded that the gain in PFS of 5.9 months observed with ixazomib was considered clinically meaningful. Concerning the possible uncertainty about the magnitude of the effect, this uncertainty was acceptable given the favourable toxicity profile, and considering that ixazomib is the first agent to allow oral triple combination therapy in this patient population which represents a therapeutic innovation in terms of convenience for patients. Therefore, the benefit–risk for ixazomib in combination with lenalidomide and dexamethasone was considered positive, although the efficacy evidence was not as comprehensive as normally required.

Multiple myeloma as a major cause of false-positive galactomannan tests in adult patients with cancer

2016 ◽  
Vol 72 (2) ◽  
pp. 233-239 ◽  
Author(s):  
Jae-Hoon Ko ◽  
Kyong Ran Peck ◽  
Ji Yong Lee ◽  
Sun Young Cho ◽  
Young Eun Ha ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
False Positive ◽  
Adult Patients ◽  
Patients With Cancer
Sign in / Sign up

Export Citation Format

Share Document